Updated on 6 September 2012
At present, the company generates its revenue from contract research done with the usage of highly customized tools, validation and data annotation approaches. The demonstration of the company's reliable and reproducible algorithmic approaches helped the company to bag some highly challenging contract research projects, which facilitated its operations and establishment of the R&D pipeline flow. Later, the company also received R&D grants that further enhanced its endeavor to develop in-house products.
"We have handled challenging and very successful contract research projects for our customers and scientists," says Mr Kumar. "We have worked from designing the analysis to develop the new methods and annotation systems to deliver the best possible research outcomes to researchers using systems biology, transcriptomics and next generation sequencing data analysis. We believe that the research services delivered through the guidance of experienced computational biologists and through interactive communication makes a big difference in achieving the exceptional computational and related biological results." BioCOS has done some contract research projects for the JNCASR in the area of malaria, for National University of Singapore and for some research labs in Europe in the areas of NGS data analysis.
The company is now planning to launch its products in the market and generate revenue. One of them, an integrated product for which a name has not been finalized yet, can handle, manage and analyze transcriptome data (RNA-SEQ and microarray), genome (DNA-Seq-wgs, exome-seq and SNP arrays) and DNA-protein binding (Chip-Seq and Chip-on Chip). The product has various pin-pointed foci to solve the critical problems of the high throughput data analysis, such as capturing more number of isoforms (discovery of novel protein isoforms in disease conditions), more reliable method to capture altered transcription from RNA-sequencing data, identification of structural variation with higher precision, disease specific association analysis and identification of protein-binding sites on genome (with a unique approach to handle repeats).
"Using the novel capabilities of computational methods in our product, we have been providing discovery-oriented research, support and services to highly specialized research labs in India and abroad and are looking forward for more applied and useful alignment with pharma companies now," says Mr Kumar. In April 2012, a paper was submitted in Nucleic Acid Research by the company's associate Ecole Normale Superieure de Lyon, France. The research completely utilized BioCOS' Chip-Seq algorithm.
The ongoing development of iMNET (another product under development) for systems biology and pathway modeling from molecular data is focused on specific human diseases (primarily on metabolic syndrome, CVD, type 2 diabetes, diabetic complications, malaria and some cancers), primary and secondary pathway interactions and physiological mechanisms of some plants). Another scientific R&D paper with company's scientific associations and collaboration with JNCASR Bangalore is under review in Cancer Science which utilized the methods and algorithms of iMNET.